James Favaloro

683 total citations
18 papers, 500 citations indexed

About

James Favaloro is a scholar working on Hematology, Immunology and Oncology. According to data from OpenAlex, James Favaloro has authored 18 papers receiving a total of 500 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Hematology, 9 papers in Immunology and 7 papers in Oncology. Recurrent topics in James Favaloro's work include Multiple Myeloma Research and Treatments (6 papers), CAR-T cell therapy research (4 papers) and Platelet Disorders and Treatments (4 papers). James Favaloro is often cited by papers focused on Multiple Myeloma Research and Treatments (6 papers), CAR-T cell therapy research (4 papers) and Platelet Disorders and Treatments (4 papers). James Favaloro collaborates with scholars based in Australia and United States. James Favaloro's co-authors include John Gibson, Hayley Suen, P. Joy Ho, Ross Brown, Derek N.J. Hart, Phillip D. Fromm, Shihong Yang, Douglas Joshua, Najah T. Nassif and Narelle Woodland and has published in prestigious journals such as Blood, Frontiers in Immunology and American Journal of Clinical Pathology.

In The Last Decade

James Favaloro

15 papers receiving 495 citations

Peers

Countries citing papers authored by James Favaloro

Since Specialization

Citations

This map shows the geographic impact of James Favaloro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Favaloro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Favaloro more than expected).

Fields of papers citing papers by James Favaloro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Favaloro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Favaloro. The network helps show where James Favaloro may publish in the future.

Co-authorship network of co-authors of James Favaloro

This figure shows the co-authorship network connecting the top 25 collaborators of James Favaloro. A scholar is included among the top collaborators of James Favaloro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Favaloro. James Favaloro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Reduced Chimeric Antigen Receptor T Cell Expansion Postinfusion Is Associated with Poor Survival in Patients with Large B Cell Lymphoma after Two or More Therapies 2025 ·Transplantation and Cellular Therapy ·Edward Abadir, (unknown), (unknown), Sachin Gupta, (unknown), (unknown), (unknown), (unknown), James Favaloro, Esther Aklilu, Christina Brown, Christian Bryant, Scott Dunkley, Derek McCulloch, Stephen Larsen, (unknown), (unknown), P. Joy Ho	3
2	Real-world Australian experience with tisagenlecleucel for relapsed/refractory diffuse large B-cell lymphoma—importance of pre-CAR-T optimization 2025 ·Frontiers in Oncology ·(unknown), (unknown), (unknown), (unknown), Christina Brown, Christian Bryant, Scott Dunkley, Derek McCulloch, (unknown), James Favaloro, (unknown), (unknown), Stephen Larsen, Edward Abadir	0
3	Single cell analysis of the CD8<sup>+</sup> T-cell compartment in multiple myeloma reveals disease specific changes are chiefly restricted to a CD69<sup>-</sup> subset suggesting potent cytotoxic effectors exist within the tumor bed. 2023 ·Haematologica ·James Favaloro, Christian Bryant, Edward Abadir, Samuel Rawson Gardiner, Shihong Yang, (unknown), Najah T. Nassif, Lisa M. Sedger, Richard Boyle, Douglas Joshua, P. Joy Ho	2
4	Treg and Oligoclonal Expansion of Terminal Effector CD8+ T Cell as Key Players in Multiple Myeloma 2021 ·Frontiers in Immunology ·Douglas Joshua, Slavica Vučković, James Favaloro, (unknown), Shihong Yang, Christian Bryant, John Gibson, (unknown)	14
5	Targeting CD83 in mantle cell lymphoma with anti‐human CD83 antibody 2020 ·Clinical & Translational Immunology ·Ziduo Li, Edward Abadir, (unknown), Candice Clarke, Christian Bryant, Wendy A. Cooper, Geoffrey A. Pietersz, James Favaloro, Pablo A. Silveira, Derek N.J. Hart, Xinsheng Ju, Georgina J. Clark	3
6	How we diagnose 2M von Willebrand disease (VWD): Use of a strategic algorithmic approach to distinguish 2M VWD from other VWD types 2020 ·Haemophilia ·Emmanuel J. Favaloro, Soma Mohammed, (unknown), Susan Oliver, (unknown), James Favaloro, Jennifer Curnow	15
7	Evaluation of human platelet lysate (HPL) as a substitute for foetal bovine serum (FBS) and recombinant proteins for the growth and maintenance of bone marrow derived mesenchymal stromal cells (BM-MSC) 2019 ·Cytotherapy ·James Favaloro, (unknown), (unknown), (unknown), Janet L. Macpherson, (unknown), (unknown), Denese C. Marks, (unknown)	0
8	Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma 2014 ·Leukemia & lymphoma ·James Favaloro, (unknown), Ross Brown, Shihong Yang, Hayley Suen, Narelle Woodland, Najah T. Nassif, Derek N.J. Hart, Phillip D. Fromm, Claire Weatherburn, John Gibson, P. Joy Ho, Douglas Joshua	91
9	Myeloid derived suppressor cells are expanded in patients with multiple myeloma, induce Treg cells and delay T-cell recovery post transplantation 2014 ·Cytotherapy ·(unknown), James Favaloro, (unknown), (unknown), (unknown), Hayley Suen, Claire Weatherburn, Justin T. Gibson, (unknown), D. Joshua	1
10	Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state 2013 ·Leukemia & lymphoma ·James Favaloro, Ross Brown, Esther Aklilu, Shihong Yang, Hayley Suen, Derek N.J. Hart, Phillip D. Fromm, John Gibson, (unknown), P. Joy Ho, Douglas Joshua	64
11	Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance 2013 ·Blood Cancer Journal ·Christian Bryant, Hayley Suen, Ross Brown, S Samuel Yang, James Favaloro, Esther Aklilu, John Gibson, P. Joy Ho, Harry Iland, Phillip D. Fromm, Narelle Woodland, Najah T. Nassif, Derek N.J. Hart, D. Joshua	110
12	Trogocytosis generates acquired regulatory T cells adding further complexity to the dysfunctional immune response in multiple myeloma 2012 ·OncoImmunology ·Ross Brown, Hayley Suen, James Favaloro, Shihong Yang, P. Joy Ho, John Gibson, Douglas Joshua	18
13	CD86+ or HLA-G+ can be transferred via trogocytosis from myeloma cells to T cells and are associated with poor prognosis 2012 ·Blood ·Ross Brown, (unknown), James Favaloro, Shihong Yang, P. Joy Ho, John Gibson, Phillip D. Fromm, Hayley Suen, Narelle Woodland, Najah T. Nassif, Derek N.J. Hart, Douglas Joshua	84
14	Blockade of the Hedgehog Signaling Pathway by the Novel Agent NVP-LDE225 Induces Differentiation, Prevents De-Differentiation and Inhibits Proliferation of Multiple Myeloma Stem Cells in Vitro 2012 ·Blood ·Shihong Yang, Ross Brown, (unknown), Hayley Suen, James Favaloro, John Gibson, (unknown), Douglas Joshua	2
15	Diagnosis and Management ofvon Willebrand Disease in Australia 2011 ·Seminars in Thrombosis and Hemostasis ·Emmanuel J. Favaloro, Roslyn Bonar, James Favaloro, Jerry Koutts	13
16	Ten Year Survivors of Multiple Myeloma Demonstrate a Differential Expression of Immunological Biomarkers Including a High Incidence of Cytotoxic T-Cell Clones Which Have Not Acquired Myeloma-Associated Anergy, 2011 ·Blood ·Christian Bryant, Ross Brown, Shihong Yang, Hayley Suen, Esther Aklilu, James Favaloro, Derek N.J. Hart, Phillip D. Fromm, Narelle Woodland, Najah T. Nassif, Harry Iland, John Gibson, P. Joy Ho, Douglas Joshua	1
17	Reassessment of ABO Blood Group, Sex, and Age on Laboratory Parameters Used to Diagnose von Willebrand Disorder 2005 ·American Journal of Clinical Pathology ·Emmanuel J. Favaloro, (unknown), Jane McDonald, (unknown), Leanne Easton, James Favaloro	79
18	Reassessment of ABO Blood Group, Sex, and Age on Laboratory Parameters Used to Diagnose von Willebrand Disorder 2005 ·American Journal of Clinical Pathology ·Emmanuel J. Favaloro, (unknown), Jane McDonald, (unknown), Leanne Easton, James Favaloro	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact